Introduction
============

Differential marking at primary differentially methylated regions (DMRs) (also known as the imprinting control regions, ICRs) in a parent-of-origin manner is a key feature of all imprinted genes. Most ICRs overlap with CpG Island (CGIs) and the imprints at these regions are established during gametogenesis and are maintained throughout development (Morgan et al., [@B30]; Hutter et al., [@B19]; Lim and Ferguson-Smith, [@B27]). Although DNA methylation at the ICR is key for the reciprocal expression of these genes, differences in histone modifications at the ICR of the two parental chromosomes are also found to contribute to the reciprocal expression profiles (as reviewed in Kacem and Feil, [@B22]). The frequent presence of tandem repeats, simple repeats, and long interspersed nuclear elements (LINEs) in the vicinity of imprinted regions is another common feature of imprinted genes (Allen et al., [@B1]; Hutter et al., [@B19]). Tandem repeat elements tend to occur more frequently within or adjacent to CGIs associated with imprinted genes than they do with CGIs of biallelically expressed genes (Hutter et al., [@B19]). Transcription factors and chromatin insulators, Yin--Yang 1 (YY1) and CTCF, are other common features of imprinted genes and are often present within the ICR. They have prominent roles in the epigenetic modifications and transcriptional control of associated imprinted genes (Filippova et al., [@B13]; Kim et al., [@B23]). However, it is the ICR that is the key feature of imprinted genes due to its regulatory function. It is the methylation status of the ICR that has direct influence on gene expression at the locus (Yoon et al., [@B52]).

*Rasgrf1* forms part of the MAPK signaling pathway and has been found to play a role in long-term memory consolidation and growth control (Brambilla et al., [@B6]; Itier et al., [@B20]). *Rasgrf1*, found on mouse chromosome 9 \[NCBI Gene ID: 19417\], is paternally imprinted and exclusively expressed from the paternal allele in the neonatal brain and liver (Dockery et al., [@B12]). A binary switch located 30 kbp upstream of the *Rasgrf1* promoter is responsible for controlling the imprint status of the gene in mice. The first component of this binary switch is a repeat unit consisting of 40 copies of a 41-bp tandem repeat element which is responsible for establishing methylation of the second component of the switch, the DMR (Holmes et al., [@B17]). This DMR serves as a CCCTC-binding factor (CTCF) binding site on the unmethylated maternal allele. Binding of a CTCF protein blocks enhancer-to-promoter interactions resulting in the silencing of the maternal allele of *Rasgrf1*. On the paternal allele, the CTCF binding factor is unable to bind to the methylated DMR resulting in expression of *Rasgrf1* from the paternal allele (Yoon et al., [@B51]).

The mouse DMR is a primary DMR established in the male germline (Yoon et al., [@B52]). It is located between *Rasgrf1* and a brain-specific micro-RNA (*Mir-*184) that is imprinted and expressed from the paternal allele in the brain (Nomura et al., [@B33]). Both these genes have human homologs and are transcribed in opposite directions. The mouse and human genomes display conserved synteny of *Rasgrf1* and *Mir-*184.

The human ortholog of *Rasgrf1* is found on chromosome 15 \[NCBI Gene ID: 5923\] but its imprint status is unknown. A recent study by Yuen et al. ([@B53]) set out to identify parent-of-origin specific methylation at many loci, including *RASGRF1*. While the results indicated some tissue-specific differential methylation ranging from 5 to 35% in trophoblast and mesenchyme tissue at this locus, there was no allele-specific or parent-of-origin specific differential methylation (Yuen et al., [@B53]). The aim of this study was to determine whether the human *RASGRF1* gene is associated with a DMR and whether this DMR is paternally methylated. In order to assess the potential imprint status of the human *RASGRF1* locus, a number of computational assessments were done to identify key imprinting features, while pyrosequencing analysis was used to assess the methylation status of various CGIs surrounding *RASGRF1*.

Methodology
===========

Computational assessment
------------------------

### Searching for sequence similarity

The BLAST-like alignment tool (BLAT) was used to identify sequence similarity using the mouse DMR \[NCBI Reference Sequence: NT_039476.7\] and the 40 copies of the 41-bp tandem repeat element unit as query sequences and comparing them against the human genome on Ensembl. The Ensembl database can be found at <http://www.ensembl.org/index.html>.

### Identification of CTCF binding sites

Knowing that the mouse *Rasgrf1* DMR is regulated by a CTCF binding protein (Yoon et al., [@B51]), a starting point for assessment was to identify all CTCF binding sites within human *RASGRF1* and between *RASGRF1* and the *MIR*-184. The *in silico* CTCF [b]{.smallcaps}inding site database (CTCFBSDB; <http://insulatordb.uthsc.edu/storm.php>) contains both experimentally identified and computationally predicted CTCF binding sites. The query sequence was uploaded in the CTCFBS prediction tool. This tool searches the query sequence for CTCFBS core motifs, which are represented by position weight matrices (PWM). A match between a query sequence and a PWM is represented by a score that corresponds to the log-odds of the observed sequence being generated by the motif versus being generated by the background. A large positive score is indicative of a good match for a potential CTCFBS.

### Identification of evolutionary conserved regions among various species

The mouse DMR is located between *Rasgrf1* and a brain-specific micro-RNA (*Mir-184*). The mouse and human genomes display conserved synteny of *Rasgrf1* and *Mir-*184. Identifying regions of conservation between these two genes in multiple species could suggest the presence of regulatory elements. The start co-ordinate of *Rasgrf1* (mouse chr9: 89,804,613 \[NCBI37/mm9\]; human chr15: 77,041,341 \[NCBI36/hg18\]) and the start co-ordinate of *Mir-*184 (mouse chr9: 89,697,098 \[NCBI37/mm9\]; human chr15: 77,289,185 \[NCBI36/hg18\]), in mice and in humans, was obtained from the UCSC Genome Browser and used in the evolutionary conserved region (ECR) browser to visualize conservation-profiles (Ovcharenko et al., [@B36]). These co-ordinates gave a defined region in which the mouse DMR lies. Hence, the mouse was used as a base genome first, followed by using the human (hg18) as a base genome. The ECRs were identified using a minimum identity of 70% per 100 bp sequence. The ECR browser can be found at <http://ecrbrowser.dcode.org/whilst> the UCSC Genome browser is accessible at <http://genome.ucsc.edu/index.html>.

### Searching for CpG islands as potential sites for differential methylation

It is known that DMRs in mice have an average G + C content of 54%, suggesting that these regions are generally CpG rich (Kobayashi et al., [@B26]). Identifying CpG rich regions between the human *RASGRF1* and *MIR*-184 would allow for identification of possible DMRs that would need to be validated in the laboratory.

A CGI Prediction tool, part of UCSC's bioinformatic tools, was used to identify CGIs between *RASGRF1* and *MIR-184*. All CGIs are scored quantitatively based on their CGI strength. High CGI strength is indicated by:

1.  An absence of DNA methylation

2.  Presence of promoter activity

3.  Open chromatin structure.

The scores allow *bona fide* CGIs -- which have high CGI strength -- to be distinguished from CpG rich regions devoid of *bona fide* CGI characteristics (Bock et al., [@B5]). The best indicator of CGI strength and most predictive of *bona fide* CGI is the "combined epigenetic score," which can assume one of three scores:

-   0.67 -- high confidence for at least two of the three high CGI strengths

-   0.50 -- equal chance of the CGI to be a *bona fide* island or a false positive

-   0.33 -- high confidence for at least one of the three high CGI strengths (Bock et al., [@B5]).

The CGI Prediction tool can be found as a link in the eleventh paragraph of the "Custom Annotation Tracks" page. This page can be found by clicking on the "Custom Annotation Tracks" tab on the panel on the left on the UCSC Genome Browser homepage.

### Search for tandem repeats within and adjacent to predicted CpG islands

The presence of tandem repeats within or adjacent to the CGIs predicted using the CGI Prediction Tool would allow for the identification of CGIs that could serve as potential ICRs.

The sequences of the CGIs, together with 1000 bp up- and downstream of the CGI regions, were used in the tandem repeat finder (TRF) program (version 4.03) to identify tandem repeats. The reason behind using 1000 bp up- and downstream was that tandem repeats associated with ICRs are either found within or adjacent to the ICRs (Thorvaldsen et al., [@B45]; Okamura et al., [@B35]; Takada et al., [@B44]). The repeats associated with *Rasgrf1* in mice are found within the ICR (Brideau et al., [@B7]).

This program utilizes an algorithm to detect tandem repeats and does not require the need to specify the repeat pattern or repeat size. The repeats are modeled based on the percentage identity and frequency of indels between adjacent repeat copies in the sequence (Benson, [@B3]). Default parameters were used for this study. The TRF program can be found at <http://tandem.bu.edu/trf/trf.html>.

Molecular assessment
--------------------

### Study participants

The methylation status of the putative DMRs was assessed using peripheral human blood (*n* = 10) and human sperm (*n* = 8) samples from unrelated participants, after obtaining written informed consent. Ethics approval for sample collection was obtained from the University of the Witwatersrand, Committee for Research on Human Subjects -- Medical (M050706 and M090555, respectively).

### DNA extraction and bisulfite modification

The blood samples were extracted using the salting-out procedure (Miller et al., [@B29]) while the sperm samples were extracted using the supplementary protocol "Purification of DNA from epithelial cells mixed with sperm cells" of the QIAamp^®^ DNA Micro Kit (Qiagen, Valencia, CA, USA). The DNA samples (400 ng) were subjected to bisulfite modification using the EZ DNA Methylation Gold™ Kit (Zymo Research, Orange, CA, USA) in accordance with manufacturers' instructions.

### PCR amplification for pyrosequencing reactions

Two known imprinted loci were used as controls in this experiment. While *SNRPN* (a maternally imprinted gene), was used as a measure in sperm cell DNA for potential contamination with somatic cell DNA and expected to by unmethylated in sperm DNA, IG-DMR (a paternally imprinted gene) was expected to be fully methylated in sperm DNA.

All amplicons were generated in a 50-μl reaction containing 2 μl of bisulfite-treated DNA, 0.2 μM each of the forward and reverse PCR primers (primers are listed in Table [1](#T1){ref-type="table"}) and 0.02 μM of the universal primer, 0.125 mM deoxynucleoside triphosphates (Bioline, London, UK), 2.0 mM MgCl~2~, 1× Buffer (Applied Biosystems, NJ, USA), 1 M Betaine (Sigma-Aldrich, Seelze, Germany), and 1 U of AmpliTaq Gold (Applied Biosystems, NJ, USA). For IG-DMR, a nested PCR was performed, first with the outer primer set and the same reaction mix as above. The second PCR was set up using 2 μl of round one PCR product, the inner primer set and the reaction mix as above.

###### 

**PCR primers for pyrosequencing PCR reactions**.

  Locus                    Primer sequence (5′--3′)                                        Amplicon length (bp)[^‡^](#tfn1){ref-type="table-fn"}   Annealing temperature (°C)
  ------------------------ --------------------------------------------------------------- ------------------------------------------------------- ----------------------------
  ***CGI_1973a***                                                                                                                                  
  Forward                  GTGCGGAAAGATGGTGTTTT                                            269                                                     60
  Reverse (Biotin)         CTCTCATTCGCCTACACAATTAC[\*](#tfn2){ref-type="table-fn"}                                                                 
  ***CGI_1973b***                                                                                                                                  
  Forward                  GAGGGAGGGTAGGGTTTGAGTG                                          292                                                     63
  Reverse (Biotin)         AACCCCAATACCCGAAAAATAC[\*](#tfn2){ref-type="table-fn"}                                                                  
  ***CGI_1974***                                                                                                                                   
  Forward                  GGTTTGTTTGGGTTTAGTAGAGAA                                        235                                                     60
  Reverse (Biotin)         ACAACCTACCTTCAAAATCATCTC[\*](#tfn2){ref-type="table-fn"}                                                                
  ***CGI_1975a***                                                                                                                                  
  Forward                  AGGAGAGAAGATGGAATTTGATT                                         186                                                     59
  Reverse (Biotin)         AATTTCCCCACACTCCTAAAATAA[\*](#tfn2){ref-type="table-fn"}                                                                
  ***CGI_1975b***                                                                                                                                  
  Forward (Biotin)         TTAGGAGTGTGGGGAAATTATTG[\*](#tfn2){ref-type="table-fn"}         110                                                     59
  Reverse                  TCTCTCCCTTCAAAACACAAAAT                                                                                                 
  ***SNRPN***                                                                                                                                      
  Forward                  AGGGAGTTGGGATTTTTGTATT                                          261                                                     58
  Reverse (Biotin)         CCCCAAACTATCTCTTAAAAAAAAC[\*](#tfn2){ref-type="table-fn"}                                                               
  **IG-DMR**                                                                                                                                       
  Forward-outer (Biotin)   GTTAAGAGTTTGTGGATTTGTGAGAAATG[\*](#tfn2){ref-type="table-fn"}   452                                                     57
  Reverse-outer            CTAAAAATCACCAAAACCCATAAAATCAC                                                                                           
  Forward-inner (Biotin)   TTTATTGGGTTGGGTTTTGTTAG[\*](#tfn2){ref-type="table-fn"}         290                                                     58
  Reverse-inner            AACCAATTACAATACCACAAAATT                                                                                                

*^‡^Amplicon length includes the 23 bp complementary tag sequence*.

*\*A 23 bp complementary tag (5′-GACGGGACACCGCTGATCGTTTA-3′) was added to the 5′ end of all biotin-labeled primers (Colella et al., [@B9])*.

PCR was performed in a GeneAmp^®^ 2720 thermal cycler (Applied Biosystems, NJ, USA) with the following conditions for all reactions; 95°C for 5 min, followed by 50 cycles of 95°C for 15 s, Ta°C for 30 s \[see Table [1](#T1){ref-type="table"} for annealing temperatures (Ta °C)\], and 72°C for 15 s; with a final extension step of 72°C for 5 min; and a final hold at 15°C. The PCR amplifications for each sperm sample and each blood sample was performed in duplicate and triplicate, respectively.

### Pyrosequencing reactions and data analysis

Pyrosequencing reactions were performed using the PyroMark^®^ Gold Q96 Kit (Qiagen, Valencia, CA, USA). Single-stranded biotinylated PCR products were prepared for pyrosequencing by use of the Vacuum Prep Tool following the manufacturer's instructions. The sequencing primers used for each pyrosequencing assay are listed in Table [2](#T2){ref-type="table"}. The pyrosequencing assays were designed to include several internal controls for bisulfite treatment to evaluate the completion of the bisulfite conversion step. Pyrosequencing data were analyzed using the Pyro Q-CpG (Biotage, Uppsala, Sweden).

###### 

**Primers for pyrosequencing assays**.

  Locus         Sequencing primer sequence (5′--3′)   Number of CpG sites analyzed   Sequence to analyze[^§^](#tfn3){ref-type="table-fn"}
  ------------- ------------------------------------- ------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------
  *CGI_1973*a   F: GGTGTTTTTTTTTTATAGGG               13                             TTG**Y**G**Y**GGGTATTTATTTT**Y**GTTGTAAAG**Y**GTT**Y**GGGTTAGG**Y**G**Y**GGTTTGTTT **Y**GGGT**Y**GGGG**Y**GAGTT**Y**GTTGTTTTTTG**Y**GGTAGATAG**Y**GATG
  *CGI_1973*b   F: GGAGGTATTAAGTTGTA                  8                              GTTTG**Y**G**Y**G**Y**GGTTTTG**Y**GTTT**Y**GG**Y**GGGGTTG**Y**GTG**Y**GTGTGTTTTTGTT
  *CGI_1974*a   F: GATTAGTTTTTTATAGTGTT               3                              **Y**GGTTTTGTAGTTTGAAGGTTTGAGAATAT**Y**GG**Y**GGGGAGTGGGTG
  *CGI_1974*b   F: GTGGGTGTATGGGAAG                   4                              GA**Y**GATGGTTTTA**Y**GGTTTTGT**Y**GTTAA**Y**GGTGGTTTTTAGAGATAATGTG
  *CGI_1975*a   F: AGAGTTTTTTTTGAAGGTAG               4                              **Y**GAGAGGGG**Y**GTTTA**Y**GTGGT**Y**GATTTATAGAGTT
  *CGI_1975*b   R: CCCTTCAAAACACAAAAT                 3                              TC**R**CATAAAAC**R**TAAAACTAAACCCTCCCC**R**TATTTTTAAA
  *SNRPN*       F: GTAGAGGTAGGTTGG                    4                              **Y**G**Y**GTATGTTTAGG**Y**GGGGATGTGTG**Y**GAAG
  IG-DMR        R: CAATTACAATACCACAAAAT               7                              TAC**R**AATTTAAC**R**AACC**R**C**R**AACAACTAAC**R**AACCACTC**R**CAATTAACAA ATC**R**CTAACAATTAACAAACCATAAACAA

*^§^The sequence to analyze is immediately 3′ to the sequencing primer binding site on the biotinylated strand*.

*The positions of the CpG sites analyzed are shown by their IUPAC codes in bold font*.

Results
=======

Computational assessment
------------------------

### Searching for sequence similarity

The BLAST algorithm was used to identify regions in the human genome that had sequence similarity to the mouse DMR and the 40 copies of the 41 bp repeat element. No sequence similarity was identified.

### Identification of CTCF binding sites

REN_20, MIT_LM2, MIT_LM7, and MIT_LM23 are PWM motif sequences that correspond to CTCF binding sites (Kim et al., [@B25]; Xie et al., [@B50]). The *in silico* CTCFBS prediction tool used these four motifs to search for putative CTCF binding sites in a region spanning 249841 bp (Ensembl co-ordinates chr 15: 79252289--79502130 \[release 61, GRCh37.p2\]), this region included *RASGRF1* and 118915 bp upstream of the gene to the first base of *MIR*-184. Four putative CTCF binding sites were identified each with a PWN score greater than 3.0 (Table [A1](#TA1){ref-type="table"} in Appendix). A score greater than 3.0 indicates that the putative CTCF binding site matches more closely to the PWM motif compared with the random background sequence (Pan and Phan, [@B37]). The putative CTCF binding site sequences corresponding to REN_20 and MIT_LM7 were found within *RASGRF1*. MIT_LM2 and MIT_LM23 were both found in the intergenic region between *MIR*-184 and *RASGRF1*.

### Identification of evolutionary conserved regions among various species

The mouse genome was selected as the base genome and the intergenic regions between *Rasgrf1* and the *Mir-*184, within which the mouse DMR lies, was visualized for conservation-profiles. The mouse genome was compared to eight vertebrate species including *Homo sapiens* (humans), *Pan troglodytes* (chimp), *Macaca mulatta* (rhesus macaque), *Xenopus tropicalis* (frog), *Gallus gallus* (chicken), *Fugu rubripes* (pufferfish), and the *Monodelphis domestica* (opossum). A number of conserved intergenic regions were identified (not shown). We used the mouse DMR co-ordinates (chr9: 89774524--89774827) from UCSC to search for conservation between species in the ECR browser. This DMR was not found to be conserved in any of the eight vertebrate species. The human genome (hg18) was then used as a base genome and the region between *RASGRF1* and *MIR-*184 was assessed to identify evolutionary conserved intergenic regions. The intergenic region at the promoter of *RASGRF1* was conserved in five of eight species while the first coding exon was found to be conserved in all eight vertebrate species. The *MIR-*184 was conserved in five of the eight species.

### Searching for CpG islands as potential sites for differential methylation

All the CGI tracks were viewed simultaneously on UCSC's CGI prediction tool. We only focused on the panel containing combined epigenetic scores. The reason behind choosing this specific score is that it provides a precise estimate of CGI strength. The CGI strength indicates the CGI's inherent tendency to exhibit an open and transcriptionally competent chromatin structure (Bock et al., [@B5]). Three CGIs were identified between the human *RASGRF1* and *MIR-*184: CGI_1973 (chr15: 77168729--77171326) at the promoter of *RASGRF1*; CGI_1974 (chr15: 77258299--77258552) and CGI_1975 (chr15: 77269392--77269597) \[NCBI36/hg18\].

### Identification of tandem repeats within or adjacent to CpG islands

The TRF program only detects repeats which occur in a head-to-tail manner (Hutter et al., [@B19]). Only one out of the three CGIs identified, using the CGI Prediction tool, had direct tandem repeats associated with it. There were a total of eight repeat elements found within and directly adjacent to CGI_1973 (Table [A2](#TA2){ref-type="table"} in Appendix). However, the TRF program identifies overlapping repeat elements therefore two elements were regarded as one if the smaller one overlapped with the larger one. The smaller repeat motif was chosen as a consensus sequence (Hutter et al., [@B19]).

Molecular assessment of the putative CpG islands which could serve as sites of differential methylation
-------------------------------------------------------------------------------------------------------

Bisulfite-treated PCR products for each of the three CGIs and the two control loci were quantitatively assayed using pyrosequencing technology. Pyrosequencing was performed on PCR products from sperm (in duplicate on *n* = 8) and blood (in triplicate on *n* = 10) DNA samples, respectively. The C (methylated) and the T (unmethylated) alleles were quantified and subsequently expressed as a percentage. Figure [1](#F1){ref-type="fig"} illustrates the methylation percentages, for *RASGRF1* CGIs, in each tissue type for each region evaluated.

![**A schematic representation of *RASGRF1* and *MIR*-184 and the positions of the putative CpG islands relative to the two genes**. The box and whisker plots **(A--F)** represent the methylation percentages for individual CpG sites for the sperm (*n* = 8) and blood (*n* = 10) samples, respectively. The red arrows denote the CTCF binding sites while the purple arrows denote the tandem repeats associated with CGI_1973. The lines beneath the CGIs represent the approximate size of these regions relative to the other features in the region.](fgene-03-00041-g001){#F1}

Due to the size of CGI_1973, found at the promoter of *RASGRF1*, a smaller region found to be rich in CG dinucleotides within this CGI was selected for further analysis. This smaller region was then split into two sub-regions CGI_1973a and CGI_1973b (bordering exon1 of *RASGRF1*) and each was assayed separately. The results were analyzed together. CGI_1974 and 1975 were difficult regions not easily amenable to pyrosequencing and therefore CGI_1974 was covered using two sequencing primers while CGI_1975 was amplified in two separate PCR reactions using two sets of PCR primers.

The entire CGI_1973 region was 2598 bp in length with a G + C content of 64%. However, only a region spanning 515 bp with a G + C content of 70% was investigated. CpG sites 1--13 were found to be hypomethylated in blood and sperm DNA. The methylation percentages for blood samples were very variable and displayed considerable inter-site and inter-individual variation at CpG sites 14--21 (Figure [1](#F1){ref-type="fig"}A). It should be kept in mind that these CpG sites border exon1 of the *RASGRF1* gene. In comparison the methylation percentages of the sperm samples showed relative hypomethylation of this region with little or no inter-site and inter-individual variation (Figure [1](#F1){ref-type="fig"}B).

CGI_1974 was 212 bp in length with a G + C content of 56%. The mean methylation percentages of the blood and sperm samples showed relative hypermethylation (Figures [1](#F1){ref-type="fig"}C,D).

The CGI_1975 region was 231 bp in length with a G + C content of 51%. The mean methylation percentages of the blood and sperm samples showed relative hypermethylation. The blood samples showed an average methylation percentage of between 50 and 60% at CpG site 4 and the two sites (CpG 3 and 5) on either side displayed a mean methylation of between 70 and 90% (Figure [1](#F1){ref-type="fig"}E). The average methylation percentages of the sperm samples at these sites ranged between 90 and 100% except for site 5 where the methylation percentage was between 70 and 90% (Figure [1](#F1){ref-type="fig"}F).

The mean methylation of the *SNRPN* DMR was found to be negligible (2.43%) in sperm samples. The theoretical methylation value for DMRs in somatic tissue is 50% (Cooper and Constancia, [@B10]). However studies have shown that somatic DMRs display methylation levels between 35 and 65% (Woodfine et al., [@B49]). Therefore the low level of methylation at the *SNRPN* DMR within the sperm samples may suggest that the paternal allele may not be completely devoid of methylation but rather displays basal levels of methylation or that there could have been low levels of contamination with somatic cells. It was concluded that the sperm samples were not significantly contaminated with somatic cell DNA.

The IG-DMR locus was found to be hypermethylated in the sperm samples, as expected, displaying a mean methylation of 89.17%. These results confirmed that the quantitative methylation technique was working optimally.

Discussion
==========

Given the role of imprinted genes in human development and health, it is important to identify key imprinted genes in the genome and to understand how they shape the phenotype. The primary aim of this study was to determine whether the human *RASGRF1* gene has a DMR and whether this DMR is paternally methylated. Methylation analysis of three putative DMRs in the vicinity of this gene in sperm and blood samples indicate that *RASGRF1*-associated CpG rich regions do not exhibit differential methylation in a parent-of-origin manner, as is seen in its mouse counter-part.

These results demonstrate that the human genome does not contain any homologous sequences to the mouse *Rasgrf1*-associated DMR or the 40 copies of the 41 nucleotide tandem repeat element. Two of the most common features of any imprinted region are the presence of a DMR and adjacent to this, tandem repeats. It is often expected that DMRs and the tandem repeats associated with them are conserved between the mouse and human due to their key regulatory function in imprinted regions (Paulsen et al., [@B38]; Hutter et al., [@B18]). The lack of these two common features in the syntenic region between the *RASGFRF1* gene and the *MIR*-184 suggest that the expression of *RASGRF1* may not be regulated by an imprinted region in humans, as it is in the mouse.

The mouse *Rasgrf1* and the human ortholog *RASGRF1* display both organizational similarities and differences. The mouse gene contains 26 exons while the human gene possesses two extra exons. The sizes of exons and intron--exon junction sequences are highly conserved. The 5′ sequence upstream of exon 1 is not only highly conserved between the mouse and the human but is also highly conserved in other vertebrates. This is consistent with the presence of important regulatory elements in this region (de la Puente et al., [@B11]). However it should be noted that organizational similarity in the genomes of species does not necessarily relate to the conservation of imprinting between species (Okamura et al., [@B35]). As an example, the mouse and human *IGF2R* genes share conserved intronic CGIs with large direct repeats that are maternally expressed in the mouse but are biallelically expressed in humans (Kim et al., [@B24]).

The CTCF binding protein is a ubiquitously expressed 11 zinc finger protein that plays a key role in chromatin insulation and is the only protein known to exhibit enhancer-blocking activity (Bao et al., [@B2]; Williams and Flavell, [@B48]). Two of the four putative CTCF binding sites corresponding to MIT_LM2 and MIT_LM2 were located in the intergenic region between *MIR*-184 and *RASGRF1*. The position of these binding sites is consistent with a potential role of CTCF as an insulator protein (Kim et al., [@B25]). The other two putative binding sites corresponding to REN_20 and MIT_LM7 were found within *RASGRF1*. It is known that almost half of the CTCF binding sites within the human genome are located within genes and many of these segregate alternative promoters of a single gene (Kim et al., [@B25]). The protocadherin gamma locus, the T-cell receptor locus and the immunoglobulin heavy chain locus all have intragenic CTCF binding sites that segregate transcriptional start sites that display differential activities across tissues (Kim et al., [@B25]). *RASGRF1* is known to have four transcripts therefore the identification of two putative CTCF binding sites within this gene may have a role in segregating the transcriptional start sites based on their activities across various tissues. Functional studies would need to be done to determine whether these putative CTCF binding sites actually bind the CTCF protein.

In some instances CTCF binding sites are found within DMRs. An example of such a CTCF binding site is that which is present at the mouse *Rasgrf1* DMR (Yoon et al., [@B51]). Another example is the CTCF binding site present at the *H19/Igf2* ICR which serves as a primary DMR established in the germline (Szabo et al., [@B43]). The hypomethylated maternal ICR serves as a binding site for the CTCF protein. Once the protein binds to this region it acts as an insulator preventing the interactions of the enhancers with the promoter of *Igf2* (Szabo et al., [@B43]). In this study the putative CTCF binding sites were not found to occur in the predicted CGIs. This suggests that *RASGRF1*, if imprinted, would be unlikely to be regulated by a CTCF binding protein as is its mouse ortholog. However, if *RASGRF1* is imprinted in humans there are other factors, besides the CTCF binding protein which could mediate imprinting. These factors could be *cis*- or *trans*-acting and could contain multiple elements that work in synergy to establish and maintain the imprint status (Ogawa et al., [@B34]).

The mouse and human genomes display conserved synteny of *Rasgrf1* and *Mir-*184. In mice the *Rasgrf1* DMR is found in the intergenic region. The ECR browser results demonstrate that the majority of the intergenic regions are conserved in the *P. troglodytes*, *M. mulatta*, *Canis familiaris*, *Mus musculus* and *M. domestica*. The conservation of these regions across multiple vertebrate species suggests that one or more of these regions could contain possible *cis*-regulatory elements such as enhancers or repressors crucial for gene regulation (Visel et al., [@B46]; Nakagawa et al., [@B32]).

The majority of the CGIs in the mouse and human genomes are hypomethylated and a small proportion of the hypermethylated CGIs are located at imprinted loci in the germline (Henckel and Arnaud, [@B16]). The hypermethylated CGIs of potential imprinted loci are expected to display monoallelic methylation (50% methylation) in somatic tissues (Strichman-Almashanu et al., [@B42]). For a region to be regarded as a DMR, it is proposed that the following criteria need to be fulfilled: the sequence should be rich in CpG dinucleotides with an average G + C content of 54% (Kobayashi et al., [@B26]) or above and display methylation levels between 35 and 65% in somatic tissue (Woodfine et al., [@B49]) over four consecutive CpG sites (Kobayashi et al., [@B26]).

CGI_1973, a putative CGI identified using the CGI Prediction tool, is located in the 5′ sequence upstream of exon 1, a region that harbors the promoter sequence for *RASGRF1* and has been found to share high homology with the mouse sequence (de la Puente et al., [@B11]). The methylation assessment of this region in blood samples displayed a deviation from the expected 50% methylation for imprinted loci in somatic tissue, indicating that the selected CGI is not differentially methylated. This is due to the fact that CGIs associated with promoters of tissue-specific genes are generally unmethylated in both expressing and non-expressing tissues although exceptions are being identified (Bird, [@B4]; Song et al., [@B41]; Weber et al., [@B47]). It is however interesting to note that part of this CGI (CpG sites 14--21) displays great inter-individual and inter-site variation only in blood samples. The difference in methylation patterns between individuals in peripheral blood samples is unlikely to be attributed to technical errors. To test the reproducibility of the PCR and pyrosequencing results, we performed each PCR and pyrosequencing reaction in duplicate for sperm samples and in triplicate for blood samples. The similar methylation profiles observed between individuals in the sperm samples, for this region and other regions, demonstrates that our techniques were reproducible. The possible reason behind the high inter-individual variation observed in peripheral blood could be that CpG sites 14--21 in this specific region are not tightly regulated, making this region more responsive to the effects of various environmental factors including carcinogen exposures, inflammation, stress and diet which all have the ability to alter DNA methylation patterns (Jirtle and Skinner, [@B21]; Christensen et al., [@B8]; Murgatroyd et al., [@B31]).

The other two putative CGIs identified in this study, CGI_1974 and CGI_1975, lie in the intergenic region between *RASGRF1* and the *MIR-*184. Both sample types were found to be hypermethylated in these regions and showed a lack of inter-individual variation. This suggests that this region is under tight regulation and may harbor transposable elements that are normally hypermethylated in the genome (Geiman and Robertson, [@B15]; Slotkin and Martienssen, [@B40]). The methylation profiles of the sperm samples for regions CGI_1974 and CGI_1975 displayed tight methylation patterns. These results are contrary to that found by Flanagan et al. ([@B14]) who demonstrated the presence of significant inter-individual DNA methylation variation in human male germ cells. However, studies in mice and other organisms have shown that certain loci display partial epigenetic stability during meiosis which may be a possible explanation for our results (Flanagan et al., [@B14]). In somatic tissues DMRs are expected to exhibit 50% average methylation over several consecutive CpG sites (Cooper and Constancia, [@B10]). However the paternal allele, represented by the sperm samples, is found to be almost completely hypermethylated over seven CpG sites of the CGI_1975 region, with an average methylation between 90 and 100%, suggesting a possible paternal parent-of-origin effect. CpG site 4 in the blood samples assayed displayed an average methylation percentage between 50 and 60%. The surrounding CpG sites had significantly higher methylation, indicating that this is not a DMR for *RASGRF1*.

Tandem repeats are found to occur frequently within the human genome, however they tend to occur more frequently within or adjacent to CGIs associated with imprinted genes (Hutter et al., [@B19]). The tandem repeats identified using the TRF tool were found to be associated with only one of the CGIs identified, CGI_1973. This CGI is located at the promoter region of *RASGRF1* and was found to be hypomethylated both in the peripheral blood and in the sperm samples. Owing to the fact that the CGI_1973 was unmethylated in both tissue types, it can be deduced that the tandem repeats associated with this promoter CGI is not involved in establishing methylation at this locus but rather plays a role in regulating gene expression by binding transcription factors and influencing splicing efficiency, RNA stability and RNA-to-protein interactions (Martin et al., [@B28]; Shah et al., [@B39]). The presence of repeats but the absence of differential methylation at CGI_1973 in peripheral blood suggests that this CGI does not serve as a DMR for *RASGRF1*.

One of the limitations of this study is that no expression data was available to confirm the imprint status of *RASGRF1*. *Rasgrf1* is expressed in the neonatal brain and liver, in mice. Therefore, in order to assess allele-specific gene expression in humans, large numbers of neonatal human brain and liver samples would be needed to identify an individual heterozygous for a SNP within the coding region of the gene. The gene expression work was not within the scope of the current study but could be pursued in the future. In addition to the gene expression work, it would be useful to obtain DNA methylation profiles of other tissues including ovarian teratomas, brain tissue and liver tissue in the event that *RASGRF1* displays tissue-specific differential methylation.

Conclusion
==========

The CGIs evaluated in this study did not fit the criteria of being a DMR. The human *RASGRF1*-associated CpG rich regions do not exhibit differential methylation in a parent-of-origin manner. *RASGRF1* does not have the same imprinting mechanism as the mouse *Rasgrf1* locus and the human genome lacks the DMR, CTCF binding site and repeat sequences that control differential gene expression at this locus in mice.
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###### 

***In silico* predicted CTCF binding site motif sequences within *RASGRF1* and between *RASGRF1* and *MIR*-184**.

  Motif PWN[\*](#tfn4){ref-type="table-fn"}   Putative CTCF binding site sequence   Motif start location[^§^](#tfn5){ref-type="table-fn"}   Motif length   Motif orientation   PWN score
  ------------------------------------------- ------------------------------------- ------------------------------------------------------- -------------- ------------------- -----------
  REN_20                                      TGAGCCACCAGAGGGCGGAG                  182100                                                  20             \+                  22.2079
  MIT_LM2                                     ATGCCACCAGGTGGCAGTT                   1433                                                    19             \+                  20.6626
  MIT_LM7                                     TAAGCACCAGAGGGCGCTGT                  205840                                                  20             \+                  21.708
  MIT_LM23                                    TCACCACCAGGTGGCGCTTG                  25632                                                   20             \+                  25.8977

*\*The *in silico* CTCFBS prediction tool used four PWM motifs to search for putative CTCF. binding sites between *RASGRF1* and *MIR*-184*.

*^**§**^The motif start location is based on the 249 841 bp \[Ensembl co-ordinates chr15: 79252289--79502130 \[release 61, GRCh37.p2)\] query sequence and gives the exact location of the putative CTCF binding site within this sequence. In this table the motif start location uses*.

*Ensembl co-ordinate 79502130 as point 0 and all the motif start locations are relative to this point*.

###### 

**Tandem repeats detected within and adjacent to CGI_1973**.

  Period size   Copy number   Percent matches   Percent indels   Consensus sequence
  ------------- ------------- ----------------- ---------------- ----------------------------------------------------------
  12            2.6           89                0                CACACACACACG
  7             110.4         71                20               ACACACC[^§^](#tfn6){ref-type="table-fn"}
  9             86.9          72                20               ACACACACC[^§^](#tfn6){ref-type="table-fn"}
  14            56.4          69                17               ACACACACCACACA[^§^](#tfn6){ref-type="table-fn"}
  16            49.4          70                17               ACACACACACCACACA[^§^](#tfn6){ref-type="table-fn"}
  2             424.5         71                17               AC[^§^](#tfn6){ref-type="table-fn"}
  2             39.5          74                12               CA[^‡^](#tfn7){ref-type="table-fn"}
  23            2.3           86                3                CACACAACACACGCAGCACACCA[^‡^](#tfn7){ref-type="table-fn"}

*^§^Overlapping repeat elements with the smallest repeat AC overlapping with all the other repeats detected*.

*^‡^Overlapping repeat elements that can be represented by one repeat element with consensus sequence CA*.
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